Somatuline LA (lanreotide suspension intramuscular) / Ipsen, Teijin - LARVOL DELTA

Structural determination of self-assembled aggregates formed by a therapeutic cyclical peptide and an ionic surfactant in aqueous solution. (PubMed, J Colloid Interface Sci) - "We were able to conclude that lanreotide does not form mixed micelles with SDS, indicating that it lacks the amphiphilic properties required to integrate fully with SDS behaving as a cosurfactant. In contrast, lanreotide attaches to the interface of SDS micelles, resembling the interactions of polymers, proteins, and nucleic acids with surfactants."

Journal

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula (clinicaltrials.gov) - P3 | N=274 | Recruiting | Sponsor: SWOG Cancer Research Network | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025 (GlobeNewswire) - "FY 2024 total sales growth of 9.9% at CER1, or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including a 67.4% increase in the Rare Diseases portfolio, 9.2% in Neuroscience, and 7.3% in Oncology; Somatuline (lanreotide) sales grew by 5.6%, while all other products, excluding Somatuline, achieved double-digit sales growth at 12.2%; FY 2024 core operating income of €1,109m, growing 10.8% as reported, with core operating margin of 32.6% of total sales...'With the successful...U.S. launch of Onivyde, alongside multiple business development deals adding several innovative assets, we are well positioned to execute our strategic roadmap'..."

Commercial • Neuroendocrine Tumor • Pancreatic Cancer

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula (clinicaltrials.gov) - P3 | N=274 | Not yet recruiting | Sponsor: SWOG Cancer Research Network

New P3 trial • Hepatology • Oncology • Solid Tumor

Pharmac proposal to increase access to five medicines for cancer and other health conditions (NZ Doctor) - "Pharmac – Te Pātaka Whaioranga is looking to increase access to five medicines for a number of cancers, including kidney and lung cancers, and other health conditions....The proposal includes: funding lanreotide acetate....widening access to sunitinib, a targeted cancer medicine, for renal cell carcinoma (kidney cancer); updating the eligibility criteria for pazopanib....widening access to bendamustine, a chemotherapy, for relapsed or recurrent chronic lymphocytic leukaemia (blood cancer); removing the prescription restrictions on pemetrexed....Consultation on Pharmac’s funding proposal for these medicines is now open and will close 9am Monday 29 July....Following public consultation, Pharmac will consider and make a decision on the funding proposal. If approved, changes for bendamustine and pemetrexed would take effect from 1 November 2024. The dates for availability of lanreotide and changes to eligibility for sunitinib and pazopanib is still to be confirmed."

Reimbursement • Chronic Lymphocytic Leukemia • Hematological Malignancies • Kidney Cancer • Leukemia • Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

The SPINET trial is finally coming out in print. Lanreotide vs. placebo for lung NETs. I'm still bummed how poorly this important trial enrolled and that's a discussion for a different day… Bottom line: Lanreotide may work but the trial stopped early.

Quantitative analysis of therapeutic peptides by CZE using multiple sample injection in hydrodynamically closed separation system. (PubMed, Electrophoresis) - "Synthetic peptide analogs triptorelin and lanreotide are known for their pronounced clinical versatility and potency. The developed methods were also evaluated according to the novel blue applicability grade index, revealing their superior applicability. The results collectively point out the potential of the proposed methods for both quality control and clinical investigations."

Journal

A trial to assess efficacy and safety of octreotide subcutaneous depot in patients with GEP-NET (clinicaltrialsregister.eu) - P3; N=302; Ongoing; Sponsor: Camurus AB

New P3 trial • Endocrine Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor • MRI • SSTR

A clinical trial aiming to assess the safety and activity of the combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET) Studio clinico finalizzato a valutare il profilo di sicurezza e di attività di cabozantinib in combinazione a lanreotide in tumori neuroendocrini (NET) gastroenteropancreatici (GEP) e toracici (clinicaltrialsregister.eu) - P2; N=69; Ongoing; Sponsor: FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"

Clinical • New P2 trial • Neuroendocrine Tumor • Oncology • Solid Tumor • PIAS4

Somatuline: Patent expiry in December 2021 (36th Annual J.P. Morgan Healthcare Conference, Ipsen)

Patent • Neuroendocrine Tumor • Oncology • Solid Tumor

Somatuline: Patent expiry in December 2021 (36th Annual J.P. Morgan Healthcare Conference, Ipsen)

Patent • Neuroendocrine Tumor • Oncology • Solid Tumor

ACROSTART: A retrospective study of the time to achieve hormonal control with lanreotide Autogel treatment in Spanish patients with acromegaly. (PubMed, Endocrinol Diabetes Nutr) - "Real-life treatment with lanreotide Autogel resulted in early hormonal control in responding patients, with high treatment adherence and satisfaction despite disparity in starting doses and dosing intervals."

Journal • Retrospective data

Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis. (PubMed, J Oncol Pharm Pract) - P=N/A; "Lanreotide was associated with significant reductions in drug-delivery time compared to octreotide LAR, which contributed to an improvement in overall healthcare efficiency."

Clinical • Journal

Ipsen delivers strong double-digit sales growth for the third quarter of 2019 and confirms full year 2019 guidance (Businesswire) - “Somatuline sales reached €264.0 million, up 18.8%, year-on-year, driven by 20.0% growth in North America, double-digit growth in key European countries and good performance in Japan; Cabometyx sales reached €64.5 million, growing 66.3% year-on-year, driven by the good performance in all launched European countries and additional launches in Asia and Oceania; Onivyde sales reached €26.1 million, down 7.3% year-on-year, impacted by limited shipments to Ipsen’s ex-U.S. partner in the third quarter.”

Sales